A multinational pharmaceutical company Sanofi Korea has failed to qualify as a certified innovative pharmaceutical company. Fairness aside, the transparency in the process seems questionable.

Since its first certification won in 2014, the company lost its certification status after six years. Now, only three multinational companies—AstraZeneca, Janssen and Ostuka Pharmaceutical—are certified as innovative pharmaceutical companies in South Korea.

The certification is definitely not permanent; if a certified company is disqualified, then the company’s benefit should be taken away. But the problem here is that there is no known reason behind the disqualification.